Skin Care Cosmetic Material Tranexamic Acid CAS 1197-18-8 Amstat Skin-Whitening Solution Treat Chloasma

We are the most professional real "MANUFACTURER" and "SUPPLIER" of TRANEXAMIC ACID on MIC, welcome the enquiry from both Foreign and Domestic customers.
 

Description:

Product Name:TRANEXAMIC ACID

CAS:1197-18-8
Molecular Formula: C₈H₁₅N02
Molecular Mass:157.21
[Appearance]: white crystal powder, no foreign substance, no obvious odor
[Melting Point]:300ºC
[Loss on Dry]: ≤1.0%
[Residue on Ignition]: ≤0.1%
[Heavy Metal ]: ≤10ppm
[Assay Determination]: 98.0%~101.0% (dries basis)
[Related Substance]:the single impurity≤0.1%, total impurities≤2.0%
[Package and Storage Condition]: 25kg/drum, store and seal away from light

Introduction of tranexamic acid:

Tranexamic acid, also known as clotting acid, is mainly responsible for inhibiting melanin and reducing melanin, so as to prevent color deposition and prevent black spots from expanding. It also has the effect of inhibiting inflammation, and is effective for darkening and anti blackening. It can be regarded as a multi-channel whitening ingredient. It is used as skin conditioner, moisturizer and whitening agent in cosmetics. The content of this component is usually between 2% and 3%. A lot of professional bloggers say that it also has certain benefits for rosacea. Generally speaking, it's a friendly ingredient for problem skin.More details can be obtained from Hubei widely.

Characteristics of tranexamic acid:

1. Good stability

Compared with traditional whitening ingredients, tranexamic acid has high stability, acid and alkali resistance, and is not easily affected by temperature environment; No carrier protection, no transmission system damage, no stimulation.

2. The skin system is easy to absorb

It is especially suitable for lightening spots, whitening and balancing the overall skin tone. In addition to lightening the spots, tranexamic acid can also improve the transparency of overall skin color and the dullness of local skin mass.

3. It can fade black spots, yellow freckles, acne marks, etc

Black spots are caused by UV damage and skin aging and other factors. Clotting acid can inhibit the activity of tyrosinase and melanocytes, reduce the production of melanin from the basal layer of epidermis, and also has the effect of removing red spots.

4. High safety

The highest concentration in cosmetics is 2% ~ 3%.

FUNCTION:

1.Tranexamic acid is mainly used for various types of bleeding caused by acute or chronic, localized
or systemic fibrinolysis.
 

Summary
Tranexamic acid is an antifibrinolytic used to reduce or prevent hemorrhagic episodes, especially in the context of hyperfibrinolytic disorders.

Background
Tranexamic acid is a synthetic derivative of lysine used as an antifibrinolytic in the treatment and prevention of major bleeding. It possesses a similar mechanism of action to aminocaproic acid but is approximately 10-fold more potent.
It was first patented in 1957 and received its initial US approval in 1986.

Pharmacodynamics
Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin.At much higher concentrations it behaves as a noncompetitive inhibitor of plasmin similar to aminocaproic acid, a similar antifibrinolytic which is 10-fold less potent. Tranexamic acid binds more strongly than aminocaproic acid to both the strong and weak receptor sites of the plasminogen molecule in a ratio corresponding to the difference in potency between the compounds. In patients with hereditary angioedema, inhibition of the formation and activity of plasmin by tranexamic acid may prevent attacks of angioedema by decreasing plasmin-induced activation of the first complement protein (C1).
Off-target antagonism of GABA(A) receptors may be associated with the development of convulsions and hyperexcitability following tranexamic acid administration - the risk appears higher with improper administration or administration during cardiovascular surgery. Consider EEG monitoring of patients with a history of seizure

Mechanism of action
Tranexamic acid competitively and reversibly inhibits the activation of plasminogen via binding at several distinct sites, including four or five low-affinity sites and one high-affinity site, the latter of which is involved in its binding to fibrin. The binding of plasminogen to fibrin induces fibrinolysis - by occupying the necessary binding sites tranexamic acid prevents this dissolution of fibrin, thereby stabilizing the clot and preventing hemorrhage.
Absorption
The bioavailability of tranexamic acid after oral administration in humans is approximately 30 to 50% of the ingested dose and is not affected by food intake. The Cmax and Tmax following multiple oral doses (1300 mg three times daily x 5 days) were 16.41 mcg/mL and 2.5 h, respectively
 

QINGDAO HAOSAIL COA OF TRANEXAMIC ACID BP




QINGDAO HAOSAIL  INVESTED CHOLIC ACID SERIES MANUFACTURER GMP CERTICIFICATION